Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.
Several other research firms have also issued reports on GYRE. Wall Street Zen lowered shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Gyre Therapeutics currently has a consensus rating of “Hold” and an average price target of $17.00.
View Our Latest Analysis on Gyre Therapeutics
Gyre Therapeutics Price Performance
Insider Buying and Selling
In related news, CEO Ying Luo sold 10,136 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total value of $81,493.44. Following the completion of the transaction, the chief executive officer directly owned 2,565,226 shares of the company’s stock, valued at approximately $20,624,417.04. This represents a 0.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Weiguo Ye sold 12,820 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total value of $78,843.00. Following the completion of the transaction, the chief operating officer owned 700,000 shares in the company, valued at $4,305,000. The trade was a 1.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 32,535 shares of company stock valued at $219,580 in the last three months. Insiders own 9.50% of the company’s stock.
Institutional Investors Weigh In On Gyre Therapeutics
A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC boosted its holdings in shares of Gyre Therapeutics by 28.6% during the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after purchasing an additional 89,390 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after purchasing an additional 45,772 shares during the last quarter. Millennium Management LLC purchased a new position in Gyre Therapeutics during the third quarter worth approximately $267,000. State Street Corp boosted its stake in Gyre Therapeutics by 10.7% during the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after buying an additional 19,472 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in Gyre Therapeutics during the third quarter worth $111,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.
Featured Articles
- Five stocks we like better than Gyre Therapeutics
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
